Prostate cancer - Gleason; Adenocarcinoma prostate - Gleason; Gleason grade; Gleason score; Gleason group; Prostate cancer - 5 grade group
The Gleason grading system refers to how abnormal your prostate cancer cells look and how likely the cancer is to advance and spread. A lower Gleason grade means that the cancer is slower growing and not aggressive.
The first step in determining the Gleason grade is to determine the Gleason score.
Higher numbers indicate a faster growing cancer that is more likely to spread.
Currently the lowest score assigned to a tumor is grade 3. Grades below 3 show normal to near normal cells. Most cancers have a Gleason score (the sum of the two most common grades) between 6 (Gleason scores of 3+3) and 7 (Gleason scores of 3+4 or 4+3).
Sometimes, it can be hard to predict how well people will do based just on their Gleason scores alone.
A new 5 Grade Group System has recently been created. This system is a better way to describe how a cancer will behave and respond to treatment.
A lower group indicates a better chance for successful treatment than a higher group. A higher group means that more of the cancer cells look different from normal cells. A higher group also means that it is more likely that the tumor will spread aggressively.
Grading helps you and your doctor determine your treatment options, along with:
Bostwick DG, Cheng L. Neoplasms of the prostate. In: Cheng L, MacLennan GT, Bostwick DG, eds. Urologic Surgical Pathology. 4th ed. Philadelphia, PA: Elsevier; 2020:chap 9.
Epstein JI. Pathology of prostatic neoplasia. In: Partin AW, Dmochowski RR, Kavoussi LR, Peters CA, eds. Campbell-Walsh-Wein Urology. 12th ed. Philadelphia, PA: Elsevier; 2021:chap 151.
National Cancer Institute website. Prostate cancer treatment (PDQ) – health professional version. www.cancer.gov/types/prostate/hp/prostate-treatment-pdq#_2097_toc. Updated July 22, 2020. Accessed August 10, 2020.BACK TO TOP
Review Date: 5/15/2020
Reviewed By: Sovrin M. Shah, MD, Assistant Professor, Department of Urology, The Icahn School of Medicine at Mount Sinai, New York, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2022 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.